A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial
Por:
Byun, JM, Pour, L, Minarik, J, Prince, HM, Askari, E, Yeh, SP, Oriol, A, Ito, S, White, D, Shaikh, E, Green, NN, Leip, E, Viqueira, A and Quach, H
Publicada:
1 dic 2025
Ahead of Print:
1 dic 2025
Resumen:
Filiaciones:
Byun, JM:
Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
Pour, L:
Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
Minarik, J:
Univ Hosp Olomouc, Dept Hemato Oncol, Olomouc, Czech Republic
Prince, HM:
Epworth Healthcare, Melbourne, Vic, Australia
Univ Melbourne, Melbourne, Australia
Askari, E:
Hosp Univ Fundacibn Jimenez Diaz, Dept Hematol, Madrid, Spain
Yeh, SP:
China Med Univ Hosp, Hematol Dept, Taichung, Taiwan
:
Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain
Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain
Ito, S:
Yamagata Univ Grad Sch Med, Dept Internal Med 3, Div Hematol & Cell Therapy, Yamagata, Japan
White, D:
Dalhousie Univ, Div Hematol, Halifax, NS, Canada
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
Shaikh, E:
Pfizer Inc, Bothell, WA USA
Green, NN:
Pfizer Inc, Cambridge, MA USA
Leip, E:
Pfizer Inc, Cambridge, MA USA
Viqueira, A:
Pfizer SLU, Madrid, Spain
Quach, H:
Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Australia
Bronze
|